Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance

Bioventus (NYSE:BVS) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.730-0.770 for the period, compared to the consensus EPS estimate of 0.720. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $600.7 million.

Analyst Ratings Changes

Several research analysts have issued reports on BVS shares. Craig Hallum raised their target price on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday. Barrington Research upped their target price on shares of Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Friday. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $14.25.

Bioventus Trading Down 7.6%

Shares of NYSE:BVS opened at $8.41 on Friday. The stock has a 50 day moving average of $8.12 and a 200 day moving average of $7.49. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a market cap of $696.04 million, a PE ratio of -13.79 and a beta of 0.78. Bioventus has a 12-month low of $5.81 and a 12-month high of $11.25.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Solid Q4 results: revenue of $157.9M (+2.8%) with organic growth of 10%, GAAP EPS $0.21 (vs $0.00 prior year), non‑GAAP EPS $0.24, and cash from operations of $38.0M (up 97%). Management said 2026 guidance reflects continued above‑market revenue growth. Globe Newswire Release
• Positive Sentiment: FY‑2026 guidance modestly ahead of consensus on EPS (0.73–0.77 vs. consensus ~0.72) and revenue guidance of $600–$610M (around consensus). The outlook supports improved earnings and cash generation for the year. Guidance Details
• Positive Sentiment: Management set a $600M–$610M 2026 sales target and said it will accelerate investment in high‑growth areas (PNS, PRP, ultrasonics), signaling reinvestment to fuel medium‑term growth. Seeking Alpha
• Positive Sentiment: Analyst upgrades/price target raises: Craig Hallum raised its PT to $16 (buy) and Barrington Research raised its PT to $14 (outperform), both signaling increased analyst confidence and sizable upside from current levels. Benzinga Street Insider
• Positive Sentiment: Market reaction to the print: shares reacted positively to the beat/guidance when markets first digested the news (shares jumped around the release). This confirms the Q4 beat was meaningful to investors. Investing.com
• Neutral Sentiment: Earnings call materials and full transcript are available for deeper review of commentary around product trends, margin drivers and investment cadence — useful for due diligence but not new company-level catalysts by themselves. Yahoo Transcript Seeking Alpha Presentation
• Negative Sentiment: Despite the largely positive fundamentals and analyst upgrades, the stock is trading lower today — likely due to profit‑taking after the early rally, and because 2026 revenue guidance sits roughly in line with street expectations (limiting an outsized upside surprise). This short‑term selling pressure can mask the longer‑term improvements highlighted above.

Hedge Funds Weigh In On Bioventus

Several hedge funds have recently added to or reduced their stakes in BVS. Marshall Wace LLP lifted its stake in Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after purchasing an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after buying an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Bioventus by 16.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after buying an additional 1,887 shares during the period. Deutsche Bank AG lifted its stake in shares of Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after acquiring an additional 1,908 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its stake in shares of Bioventus by 6.0% during the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after acquiring an additional 3,909 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Company Profile

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.